Oppenheimer Reiterates Outperform Rating for Capricor Therapeutics (NASDAQ:CAPR)

Oppenheimer reaffirmed their outperform rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a report issued on Monday, Benzinga reports. The brokerage currently has a $15.00 price target on the biotechnology company’s stock.

A number of other analysts have also recently weighed in on CAPR. Maxim Group reaffirmed a buy rating and set a $12.00 target price on shares of Capricor Therapeutics in a research note on Tuesday, September 17th. HC Wainwright restated a buy rating and set a $40.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday, September 17th. Finally, Cantor Fitzgerald reiterated an overweight rating and issued a $8.00 target price on shares of Capricor Therapeutics in a research report on Friday, September 20th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus price target of $22.60.

Capricor Therapeutics Price Performance

Shares of CAPR opened at $10.34 on Monday. The firm has a 50 day simple moving average of $4.59 and a two-hundred day simple moving average of $5.25. Capricor Therapeutics has a one year low of $2.68 and a one year high of $12.87. The company has a market cap of $336.46 million, a P/E ratio of -11.88 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The company had revenue of $3.97 million during the quarter, compared to analyst estimates of $4.51 million. Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. On average, analysts expect that Capricor Therapeutics will post -1.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of Capricor Therapeutics stock in a transaction on Friday, September 20th. The shares were purchased at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the transaction, the insider now owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 12.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after buying an additional 200,499 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares during the period. Marshall Wace LLP acquired a new position in shares of Capricor Therapeutics in the 2nd quarter valued at about $426,000. Bank of New York Mellon Corp grew its stake in Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 9,040 shares during the period. Finally, Jump Financial LLC bought a new stake in Capricor Therapeutics in the fourth quarter worth approximately $258,000. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.